SHEL.UK

3,065

-4.49%↓

BP

514.8

-3.38%↓

DCC

6,140

0%↓

SHEL.UK

3,065

-4.49%↓

BP

514.8

-3.38%↓

DCC

6,140

0%↓

SHEL.UK

3,065

-4.49%↓

BP

514.8

-3.38%↓

DCC

6,140

0%↓

SHEL.UK

3,065

-4.49%↓

BP

514.8

-3.38%↓

DCC

6,140

0%↓

SHEL.UK

3,065

-4.49%↓

BP

514.8

-3.38%↓

DCC

6,140

0%↓

Search

Smith & Nephew PLC

Avatud

1,139.5 0.35

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1130.5

Max

1149

Põhinäitajad

By Trading Economics

Sissetulek

47M

342M

Müük

318M

3.3B

P/E

Sektori keskmine

21.306

63.807

Aktsiakasum

0.429

Dividenditootlus

3.43

Kasumimarginaal

10.36

Töötajad

16,988

EBITDA

162M

886M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+23.74% upside

Dividendid

By Acuity

Dividenditootlus

Sektori keskmine

3.43%

3.59%

Järgmine tulemuste avaldamine

4. aug 2026

Turustatistika

By TradingEconomics

Turukapital

-1.4B

9.8B

Eelmine avamishind

1139.15

Eelmine sulgemishind

1139.5

Smith & Nephew PLC Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Ettevõttest Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat